Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIb trial evaluating the efficacy and tolerability of vaginal telapristone [Proellex-V] in patients with severe menstrual bleeding associated with uterine fibroids

Next Previous
X
Search
Trial Profile

Phase IIb trial evaluating the efficacy and tolerability of vaginal telapristone [Proellex-V] in patients with severe menstrual bleeding associated with uterine fibroids

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Apr 2016

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telapristone (Primary)
  • Indications Uterine leiomyoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 12 Apr 2016 According to a Repros Therapeutics media release, once both - this vaginal and oral (see CTP 242103) studies, complete both 18 week courses of treatment, the company plans to request an end of phase II meeting with the FDA to jointly discuss plans for phase III.
    • 12 Apr 2016 Status changed from recruiting to active, no longer recruiting, according to a Repros Therapeutics media release.
    • 12 Apr 2016 Results published in a Repros Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top